**4. Future perspectives**

Cisplatin plus pemetrexed has been the mainstay of systemic treatment for MPM. A phase III trial of platinum, pemetrexed plus the anti-VEGF inhibitor, bevacizumab, showed favorable results, with prolonged PFS and OS. The National Comprehensive Cancer Network (NCCN) guidelines advocate adding bevacizumab as an option;


### *Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma… DOI: http://dx.doi.org/10.5772/intechopen.102511*

